Back to Search
Start Over
Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV.
- Source :
-
Clinical Medicine Insights: Oncology . Jan-Dec2020, Vol. 14, p1-9. 9p. 4 Charts, 4 Graphs. - Publication Year :
- 2020
-
Abstract
- BACKGROUND: Antiangiogenic agents have been shown to stimulate the immune system and cause synergistic effects with chemotherapy. Effects might be even stronger after immune-checkpoint-inhibitor (ICI) therapy. The purpose of this analysis was to evaluate the efficacy of ramucirumab plus docetaxel (R + D) as third-line treatment after failure of a first-line platinum-based chemotherapy and a second-line ICI treatment in patients with non-small-cell lung cancer (NSCLC) stage IV. METHODS: Retrospective data were collected from 9 German thoracic oncology centers. Only patients who had received at least 1 cycle of third-line R + D were included. The numbers of cycles, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were investigated. RESULTS: Sixty-seven patients met the criteria for inclusion. Third-line treatment with R + D achieved an ORR of 36% and a disease control rate (DCR) of 69%. Median PFS for third-line therapy was 6.8 months with a duration of response (DOR) of 10.2 months. A median OS of 29 months was observed from the start of first-line therapy with a median OS of 11.0 months from the start of third-line treatment. No unexpected toxicities occurred. CONCLUSION: R + D is a highly effective and safe third-line treatment after failure of second-line programmed cell death protein 1/programmed cell death-ligand 1 (PD1/PD-L1)-derived ICI therapy irrespective of NSCLC histology. As there may be synergistic effects of second- and third-line treatments, this sequence is a very suitable option for patients not treated with first-line ICI. In addition, R + D should continue to be investigated as a second-line treatment option after failure of chemotherapy plus ICI in the palliative first--line treatment. [ABSTRACT FROM AUTHOR]
- Subjects :
- *THERAPEUTIC use of monoclonal antibodies
*THERAPEUTIC use of antineoplastic agents
*DRUG efficacy
*LUNG cancer
*PLATINUM compounds
*IMMUNE checkpoint inhibitors
*RETROSPECTIVE studies
*CANCER patients
*TREATMENT effectiveness
*DOCETAXEL
*DESCRIPTIVE statistics
*DRUG synergism
*PALLIATIVE treatment
*IMMUNOTHERAPY
*THERAPEUTICS
Subjects
Details
- Language :
- English
- ISSN :
- 11795549
- Volume :
- 14
- Database :
- Academic Search Index
- Journal :
- Clinical Medicine Insights: Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 149210181
- Full Text :
- https://doi.org/10.1177/1179554920951358